TrialThe lancet. HIV2022

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.

Anna Turkova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.